Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Plant proteins – e.g. – derived from legumes – algae or...
Reexamination Certificate
1998-10-26
2002-05-14
Allen, Marianne P. (Department: 1631)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Plant proteins, e.g., derived from legumes, algae or...
C530S350000
Reexamination Certificate
active
06388056
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to compounds and methods for the prevention and treatment of microbial infection of a mammalian host through the administration of substrates for transglutaminases or antibodies against such substrates that inhibit the transglutaminase-mediated interaction of the microorganism with the mammalian host. These compounds and methods may be used preferably in the identification, prevention or treatment of microbial infection of mammalian hosts such as immunocompromised or immunosuppressed humans, for example, those having AIDS or undergoing transplantation or anti-cancer therapy.
BACKGROUND OF THE INVENTION
Whether pathogenic or opportunistic, microorganisms have evolved numerous mechanisms to facilitate their establishment and proliferation in mammalian hosts. During initial infection, the interaction of a microorganism with its mammalian host can include attachment or adhesion to the host cell surface, invasion of host cells, and elaboration of toxins, for example. In certain instances, this interaction can be nonspecific. In others, such microbial interaction involves the specific binding of the microorganism to a particular receptor or receptor complex expressed on the host cell surface. In turn, the binding event can trigger changes in the microorganism and/or the mammalian host cell, leading to the progression of infection.
The host cell functions of molecules involved in certain microbial interaction are unknown in some cases and known in others. Mammalian transglutaminases are examples of those in the latter category for which the molecular mechanism of action and/or role in host cell growth or development has been elucidated. In general, transglutaminases are enzymes that catalyze intermolecular crosslinks by the formation of highly stable isodipeptide bonds between the &ggr;-carbonyl group of glutamine and the &egr;-amino group of lysine residues, which are resistant to proteases, sodium dodecyl sulfate and heat. Epithelial cell transglutaminases are important for the formation of cornified envelopes of mature squamous epithelial cells.
Only recently have investigators shown that certain microorganisms may express proteins capable of acting as substrates for, and thus interact with, mammalian transglutaminases. One example is hyphal wall protein 1 (Hwp1), which is expressed on hyphal surfaces of the pathogenic fungus,
Candida albicans.
Hwp1 consists of an N-terminal proline and glutamine-rich repetitive amino acid sequence that is exposed on the hyphal surface, and a cell wall-anchored serine and threonine-rich C-terminus. The composition of the N-terminal amino acid repeats is reminiscent of mammalian transglutaminase substrates. It is now known that Hwp1 can serve as a substrate in transglutaminase-mediated cross-linking reactions.
Candida is an ubiquitous yeast recognized as the causative agent of candidiasis (
Candida mycosis
). At least 90% of the disorders are caused by the species
C. albicans,
which is an opportunistic yeast able only to elicit mild superficial infections in normal individuals. Fungal infections associated with severe infections of the mucous membrane and with invasive infections of individual organs are observed ever more frequently as a result of the increasing number of patients with immune defense weakness, e.g., patients with acquired immunodeficiency syndrome (AIDS) or patients undergoing immunosuppressive therapy.
If left untreated, such systemic infections frequently lead to the death of the patients. At present, the treatment for invasive infections is based on relatively few antimycotics, such as amphotericin B and flucytosine, or the azole derivatives fluconazole and itraconazole. These antimycotics cause serious, sometimes different, side effects, such as renal insufficiency, hypocalcemia and anemia, as well as unpleasant constitutional symptoms such as fever, shivering and low blood pressure.
For this reason, doctors and clinicians are interested, for achieving direct and effective therapy, in having available diagnostic procedures permitting the earliest possible identification of the fungal pathogens. Conventional methods of diagnosis are based on the in vitro cultivation of the pathogens and the identification of the fungal species by means of morphological, physiological and biochemical methods. The culturing of
C. albicans
from blood is frequently very difficult and unreliable. Although
C. albicans
can be cultured from the mouths of normal persons, the progression to mucosal candidiasis is characterized by a shift in the microbial flora that includes an increase in the number of fungi in saliva, followed ultimately by invasion and inflammation of the gastrointestinal mucosa by
C. albicans.
The clinical presentations are pseudomembranous or erythematous lesions in the oral cavity and/or esophagus.
Oropharyngeal and esophageal candidiasis are among the most frequent opportunistic fungal infections observed in human immunodeficiency virus positive (HIV+) and AIDS patients, occurring in the majority of patients. The pathogenesis is complex and is thought to involve multiple host factors that include loss of cell mediated immunity and altered phagocytic cell activity. The current status of the AIDS epidemic is one of increasing numbers of individuals infected and no cure. Many infected individuals may live for a long time with HIV in an essentially permanent immunocompromised state. Because of the loss of the cellular component of the immune system, AIDS patients are susceptible to invasion of submucosal tissue by
C. albicans.
The frequency of candidal infections may also be a result of the prophylactic use of antibacterial drugs used in AIDS patients to minimize other opportunistic infections. Candidal infections increase in severity and recur more frequently as the immunodeficiency progresses.
While treatment with antifungal drugs can be effective, the increasing frequency of resistant strains of
C. albicans,
and the systemic side effects of the drugs prompts exploration of novel strategies to interrupt the sequence of events leading to disease and to expand the repertoire of antifungal drugs. An antifungal strategy based on biological interactions between
C. albicans
and the oral mucosa would be of great benefit to those with such fungal infections, e.g., patients with long-term immunodeficiencies.
Relevant features of
C. albicans,
the most frequent cause of oral candidiasis in HIV infected patients, are persistence in the gastrointestinal mucosa and invasiveness in the presence of diminished host defenses. Although
C. albicans
is sensitive to antifungal drugs, treatment over long periods of time are required, and isolates from HIV infected patients may be more resistant than other isolates. In addition to HIV infected patients, oral candidiasis occurs in patients with leukemia or other cancers, as well as in patients with other underlying diseases. Candidiasis in denture wearers, or denture stomatities, is the commonest of all
C. albicans
associated diseases. Indeed, new approaches towards preventing or managing oral candidiasis are needed.
A feature of
C. albicans
growth that is correlated with pathogenicity in the oral cavity is the ability to transform from budding to filament-extending growth. Filamentous forms adhere more readily to buccal epithelial cells than budding yeasts, and histologically are a prominent feature of invasion of the mucosa. Knowledge of the molecular events that transform
C. albicans
to the pathogenic filamentous form as well as detailed investigations of the hyphal surface at the molecular level are necessary for understanding the pathogenesis of oral candidiasis.
In mucosal and systemic disease,
C. albicans
exists as a polymorphic set of growth forms termed yeasts, pseudohyphae and true hyphae. In mucosal disease, filamentous forms, particularly true hyphae, invade the keratinized layer of differentiated, stratified squamous epithelium. True hyphae are septate, cylindrical structures with parallel sides that are forme
Bradway Steven D.
Sundstrom Paula
Allen Marianne P.
McKenna & Cuneo LLP
Sundstrom Paula
LandOfFree
Inhibition of transglutaminase-mediated microbial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of transglutaminase-mediated microbial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of transglutaminase-mediated microbial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2914066